Phase II Iressa versus Vinorelbine (INVITE)
Study identifier:D791AC00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomised, Open Label, Parallel Group, Multi-Centre, Phase II Study of Progression Free Survival Comparing ZD1839 (IRESSA™) (250 MG Tablet) Versus Vinorelbine (30 MG/M2 Infusion) in Chemonaive, Elderly Patients with Locally Advanced (Stage IIIB) or Metastatic (Stage IV) NSCLC
Medical condition
Non-Small-Cell Lung Carcinoma
Phase
Phase 2
Healthy volunteers
No
Study drug
Gefitinib, Vinorelbine
Sex
All
Actual Enrollment
192
Study type
Interventional
Age
70 Years +
Date
Study Start Date: 01 Jul 2004
Primary Completion Date: -
Study Completion Date: 01 Feb 2006
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Contact
AstraZeneca Clinical Study Information
-
-
Investigators
Principal Investigator
AstraZeneca Iressa Medical Science Director
AstraZeneca
